TICKERNERD
Menu
VOGXHealthcare · Biotechnology

VOGX Stock Forecast: Vogenx, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$17
+8.23% on the day

The 1 Wall Street analysts covering Vogenx, Inc. hold a median 12-month price target of $55 — +214.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$259.8M
Ticker Nerd rank
2 / 100
Median analyst target
$55
Analysts covering
1
Total return, dividends reinvested
1W
−12.8%
1M
−45.3%
From high
−48.8%
From low
+34.5%
$13
$34
Range since 12 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

VOGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vogenx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
64
Revisions
37
Value
17
Growth
8
Accruals
8
Quality
5
Volatility
4
Issuance
1
Momentum
1

Size (64): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VOGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VOGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 12 Aug 2026Adjusted close, US dollars
$10$20$30$40$50$60Aug 26Aug 26Aug 26Sep 26Sep 26Sep 26Sep 26Oct 26VOGXHigh $55Median $55Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $55Median $55High $55

The green dot is the last close — the median target sits +214.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2026WBB SecuritiesInitiatesSpeculative Buy$42
1 Sept 2026Jones TradingInitiatesBuy$55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VOGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VOGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

VOGX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Aug 26Aug 26Aug 26Sep 26Sep 26Sep 26Sep 26Oct 26VOGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VOGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Vogenx, Inc. (VOGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
−96.3×

Cheaper than 99% of US stocks

EV / EBITDA
−161.3×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
157.3%

Higher than 98% of US stocks

Return on assets
−212.2%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vogenx, Inc. (VOGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vogenx, Inc. has a market value of $259.8M and an enterprise value of $240.7M.

  • Shares outstanding: 13.9M.

  • forward P/E: −11.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vogenx, Inc. employs 4 people.

market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

VOGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VOGXVogenx, Inc.$259.8M
2
ACIUAC Immune SA$259.5M
33
IPSCCentury Therapeutics, Inc.$262.3M
38
SABSSAB Biotherapeutics, Inc.$263.0M
39
LCTXLineage Cell Therapeutics, Inc.$256.6M
58
IKTInhibikase Therapeutics, Inc.$266.5M
40
PALIPalisade Bio, Inc.$252.7M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vogenx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VOGX news & analysis

Vogenx Appoints Ken Toombs to Board of Directors

Accesswire · 22 Sept 2026positive

Vogenx, Inc. announced the appointment of Ken Toombs, former CEO of PA Consulting, to its Board of Directors as an independent director and Chair of the Audit Committee, effective September 21, 2026. The appointment brings three decades of global professional services and life sciences leadership experience and broadens independent oversight as the company scales following its August 2026 initial public offering.

Why it matters — For VOGX watchers, adding an experienced, independent director and Audit Committee Chair strengthens corporate governance and oversight during the company's post-IPO scaling phase.

Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

PRNewsWire · 17 Aug 2026positive

JonesTrading Institutional Services announced it served as sole book-running manager for Vogenx, Inc.'s $81.3 million initial public offering on NASDAQ. The offering comprised 6,250,000 shares of Vogenx common stock at $13.00 per share, priced at the high end of the proposed range.

Why it matters — The IPO's completion and pricing at the high end of the proposed range is notable for Vogenx watchers as it marks the company's public market debut and reflects demand for its shares.

FAQ

Frequently asked questions about VOGX stock

What is the VOGX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Vogenx, Inc. have a median 12-month price target of $55, with estimates ranging from $55 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VOGX stock a buy right now?

Of the 1 analysts covering Vogenx, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vogenx, Inc. 2 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VOGX?

As at 8 Oct 2026, Vogenx, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (64 of 100).

Will VOGX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +214.5% from the last close, and Ticker Nerd's factor model ranks Vogenx, Inc. 2 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VOGX stock forecast for 2030?

No analyst covering Vogenx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $55 over the next 12 months.

What does Vogenx, Inc. do?

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders.

What is the latest news on VOGX?

The most recent item we track (Accesswire, 22 Sept 2026): "Vogenx Appoints Ken Toombs to Board of Directors". Vogenx, Inc. announced the appointment of Ken Toombs, former CEO of PA Consulting, to its Board of Directors as an independent director and Chair of the Audit Committee, effective September 21, 2026. The appointment brings three decades of global professional services and life sciences leadership experience and broadens independent oversight as the company scales following its August 2026 initial public offering.

Company

About Vogenx, Inc.

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. Its current work centers on treatments for post-bariatric hypoglycemia and gastroparesis, with additional research in related rare metabolic conditions. The company’s lead program is mizagliflozin, an oral small-molecule SGLT1 inhibitor designed to address abnormal glucose absorption and other metabolic pathways in the gut. Vogenx also maintains a broader pipeline that includes additional drug candidates under evaluation for metabolic disease indications. The company serves the life sciences and drug development market, where it advances investigational therapies aimed at conditions with limited treatment options. Vogenx Inc. is headquartered in Raleigh, North Carolina and operates as a focused developer of novel medicines for metabolic and gastrointestinal disease areas.

CEO Mr. James Green · 4 employees · United States · https://vogenx.com